The physician from the Dana-Farber Cancer Institute discussed the uptake of novel therapies in heavily pretreated multiple myeloma.
The phase 1b KEYNOTE-B79 trial of CYAD-101 for mCRC is expected to initiate in Q4 2021.
The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.
The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed future research with CAR T-cell therapy in multiple myeloma.
Findings from an ongoing phase 1 trial were presented at the 2021 ASGCT meeting.